Â鶹´«Ã½

    Advertisement
    Pharmaceutical Technology07:37Pfizer Vaccine Pfizer GSK
    Bloomberg Law15:36Pfizer Vaccine GSK Pfizer
    Yahoo! US18:44Pfizer Vaccine GSK Pfizer
    Dorset Echo23:14The Lancet England
    Nursing in Practice08:09The Lancet England
    PharmaTimes08:16Pfizer Vaccine WHO Pharma
    Proto Thema News18:26Pfizer Vaccine WHO Pharma
    Pharmacy Times14:34APhA Pharma
    Pharmacy Times20:58APhA Pharma
    In the last 2 hours
    Insurance News Net20:38
    In the last 6 hours
    Pharmacy Times16:15
    In the last 8 hours
    Bloomberg Law15:36
    Yesterday
    Law36023:43 3-Apr-25
    Yahoo! US18:44 3-Apr-25
    Portfolio.hu06:29 3-Apr-25
    In the last 7 days
    LabOnline00:58 2-Apr-25
    McKnight's Long-Term Care News16:54 1-Apr-25
    Business Wire (Press Release)09:24 1-Apr-25
    Pharmaceutical Technology07:37 1-Apr-25
    PMLiVE07:33 1-Apr-25
    Business Wire (Press Release)03:07 1-Apr-25
    Dorset Echo23:14 29-Mar-25
    Government of Newfoundland and Labrador (Press Release)12:31 28-Mar-25
    In the last month
    Proto Thema News18:26 27-Mar-25
    Nursing in Practice08:09 27-Mar-25
    Bournemouth Daily Echo01:20 27-Mar-25
    GlobeNewswire (Press Release)08:05 26-Mar-25
    Evening Standard10:34 25-Mar-25
    GOV.UK (Press Release)10:33 25-Mar-25
    Nature.com21:14 24-Mar-25
    PharmaTimes08:16 24-Mar-25
    Pharmacy Times14:34 23-Mar-25
    Pharmacy Times20:58 22-Mar-25
    Pharmacy Times15:47 19-Mar-25
    McKnight's Long-Term Care News17:25 17-Mar-25
    Mercopress13:04 17-Mar-25
    Pharmacy Times11:43 17-Mar-25
    Kalamazoo Gazette, Michigan08:50 14-Mar-25
    Gavi, the Vaccine Alliance07:44 14-Mar-25
    To Vima06:23 14-Mar-25
    News-Medical.Net13:37 13-Mar-25
    Eurosurveillance12:44 13-Mar-25
    Nature.com05:11 13-Mar-25
    Pharmacy Times16:22 12-Mar-25
    Business Wire (Press Release)07:02 12-Mar-25
    BioSpectrum Asia12:02 11-Mar-25
    The Michigan Daily23:21 10-Mar-25
    Journal of American Medical Associations11:50 10-Mar-25
    Journal of American Medical Associations11:44 10-Mar-25
    Business Wire (Press Release)08:04 10-Mar-25
    MailOnline20:19 8-Mar-25
    Voice Online12:18 7-Mar-25
    RTL Today11:16 6-Mar-25
    GlaxoSmithKline (Press Release)07:12 6-Mar-25
    PMLiVE07:27 5-Mar-25
    view more headlines
    4 Apr 20:38

    About our Respiratory Syncytial Virus news

    Latest news on RSV, the respiratory syncytial virus affecting infants and young children, including updates on outbreaks, prevention, treatment, and research into this common but potentially serious illness in the UK and globally.

    RSV is a highly contagious virus that causes respiratory tract infections, particularly in young children and older adults. In the UK, RSV accounts for around 33,000 hospitalizations annually in children under 5, according to recent data. The virus is also the most common cause of bronchiolitis and pneumonia in children under one year of age in the United States, as reported by the Centers for Disease Control and Prevention (CDC). While most RSV infections are mild, some cases can lead to severe complications, especially in premature infants, children with weakened immune systems, or those with underlying health conditions.

    Our RSV news feed keeps you informed about the latest outbreaks and trends in RSV cases, as reported by healthcare providers, hospitals, and public health agencies in the UK and around the world. We cover stories on the impact of RSV on families and communities, as well as the strain it places on healthcare systems during peak seasons. Stay updated on the latest recommendations and guidelines from the UK Health Security Agency and the CDC for preventing the spread of RSV, such as frequent handwashing, avoiding close contact with infected individuals, and keeping high-touch surfaces clean.

    In addition to prevention, our feed also covers the latest developments in RSV treatment and management. From supportive care measures like oxygen therapy and hydration to the use of antiviral medications and the potential for new RSV vaccines, we keep you informed about the options available for combating this illness. We also report on ongoing clinical trials and research studies aimed at improving RSV prevention, diagnosis, and treatment.

    RSV has a significant impact on families, causing anxiety and stress for parents as they care for their sick children. Our feed includes personal stories and experiences shared by families affected by RSV, highlighting the human dimension of this illness. We also cover community initiatives and support groups that provide resources and comfort to those dealing with RSV.

    As researchers work to better understand RSV and develop more effective interventions, our feed keeps you updated on the latest scientific findings and breakthroughs. From studies on the virus's structure and transmission to the development of novel therapies and vaccines, we provide comprehensive coverage of the ongoing efforts to combat RSV and improve public health outcomes.

    In recent news, the UK government has issued a tender notice to purchase up to 6.3 million vaccines and treatments to protect babies and elderly people against RSV. The plan aims to secure supplies from GSK Plc, Pfizer Inc., and AstraZeneca Plc together with Sanofi, in time for the next winter season. The tender could see the purchase of up to 3.6 million products to protect older people, around 1.3 million for infants, and as many as 1.4 million for pregnant mothers, whose protection extends to their unborn babies.

    The UK's move comes as countries race to secure supplies of the newly introduced RSV products, which have been developed after decades of research. The shots would be delivered between July 2024 and June 2026, with a possible two-year extension. The UK Health Security Agency is currently engaging with the market to assess its RSV needs and working with the National Health Service and the Department of Health and Social Care to implement a protection program.

    In the European Union, several countries have also indicated their interest in working together to bulk purchase the RSV drugs. The European Commission is currently in the exploratory phase for possible joint procurements, highlighting the growing global demand for these life-saving interventions.

    Our Â鶹´«Ã½ feed on RSV is constantly updated with the most relevant and reliable information from trusted sources, ensuring that you stay well-informed about this significant health concern affecting infants and young children. Whether you are a parent, healthcare professional, or simply interested in staying up-to-date on important health issues, this feed is your go-to resource for the latest news and developments related to RSV.


    Publication filters

    Headline Density

    Sorry, no headlines or news topics were found. Please try different keywords.